This Plain Language Summary of Publication article (PLSP) from Future Oncology describes the TROPHY-U-01 study examining sacituzumab govitecan (TRODELVY®), an antibody-drug conjugate that targets and kills cancer cells, in patients with locally advanced or metastatic urothelial cancer. This particular report focuses on Cohort 2 participants who couldn’t tolerate cisplatin chemotherapy and whose cancer progressed despite immunotherapy. All participants in this cohort received sacituzumab govitecan to evaluate its effectiveness as an alternative treatment option for this specific patient population.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy’ and was published in the Journal of Clinical Oncology.

Visit ASCO Publications using the link to read the original article.